🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

14,283 results for “B” Clear

  1. Ixabepilone + Capecitabine

    Semnur Pharmaceuticals

    Breast Cancer

    phase 3 small molecule completed

    1 trial

  2. Ixazomib

    Takeda

    Relapsed Multiple Myeloma

    phase 3 small molecule completed

    1 trial

  3. Ixazomib Citrate

    Takeda

    Multiple Myeloma

    phase 3 small molecule completed

    2 trials

  4. Ixazomib, thalidomide, & dexamethasone (ITD) re-induction

    Takeda

    Multiple Myeloma

    phase 3 small molecule active

    1 trial

  5. JEVTANA 60 mg concentrate and solvent for solution for infusion.

    Ningbo Cancer Hospital

    Patients with localized prostate cancer and high-risk features of relapse.

    phase 3 small molecule active

    1 trial

  6. JNJ 67896062, Matching Placebo for Macitentan 75 mg, JNJ 67896062, Matching Placebo for Macitentan 37.5 mg, Opsumit 10 mg film-coated tablets, Matching Placebo for Macitentan 10 mg

    Lacuna Pharma Pty Ltd

    Pulmonary arterial hypertension

    phase 3 small molecule active

    1 trial

  7. JNJ-42756493, GEMCITABINE , MITOMYCIN

    Janssen-Cilag International N.V.

    FGFR+ Intermediate-risk Non-muscle Invasive Bladder Cancer

    phase 3 small molecule active

    1 trial

  8. JNJ-54767414

    Janssen-Cilag International N.V.

    Precancerous form of blood cancer in the bone marrow

    phase 3 small molecule active

    1 trial

  9. JNJ-56021927

    Ningbo Cancer Hospital

    High-risk biochemically-relapsed prostate adenocarcinoma following radical prostatectomy.

    phase 3 small molecule active

    1 trial

  10. JNJ-56021927, Prednison acis 5 mg, Tabletten, ZYTIGA 250 mg tablets, placebo to match JNJ-56021927/Apalutamide, -

    Janssen-Cilag International N.V.

    Metastatic castration-resistant prostate cancer (mCRPC)

    phase 3 small molecule active

    1 trial

  11. JNJ-61186372, Carboplatin 10 mg/ml Intravenous Infusion, CARBOPLATIN , Pemetrexed Seacross 500 mg powder for concentrate for solution for infusion, PEMETREXED

    Janssen-Cilag International N.V.

    EGFR Exon 20ins Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  12. JNJ-61186372, Erbitux 5 mg/mL solution for infusion, Erbitux 5 mg/mL solution for infusion

    Janssen-Cilag International N.V.

    KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer

    phase 3 small molecule active

    1 trial

  13. JNJ-63723283, JNJ-63723283, Gemcitabina Accord 100 mg/ml concentrato per soluzione per infusione., JNJ-17000139, GEMCITABINE ACCORD 100 mg/ml, solution à diluer pour perfusion, Cisplatinum Accord, 1 mg/ml, koncentrat do sporządzania roztworu do infuzji., Gemcitabine100 mg/ml Concentrate for Solution for Infusion, Gemcitabin Accord 100 mg/ml Konzentrat zur Herstellung einer Infusionslösung

    Janssen-Cilag International N.V.

    Muscle-Invasive Urothelial Carcinoma (MIBC) of the Bladder

    phase 3 small molecule active

    1 trial

  14. JNJ-67896049, JNJ-67896049, Opsumit 10 mg film-coated tablets, JNJ-68150420, JNJ-67896049

    Lacuna Pharma Pty Ltd

    pulmonary arterial hypertension

    phase 3 small molecule active

    1 trial

  15. JNJ-73841937, Pemetrexed Seacross 500 mg powder for concentrate for solution for infusion, CARBO-cell® 10 mg/ml Infusionslösung, Konzentrat zur Herstellung einer Infusionslösung Carboplatin, JNJ-61186372, CARBOPLATIN , Carboplatin 10 mg/ml Intravenous Infusion, PEMETREXED

    Janssen-Cilag International N.V.

    Locally Advanced or Metastatic Non-Small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  16. JNJ-75276617, Venclyxto 100 mg film-coated tablets, matching the 100 mg (G030), matching the 30 mg (G031), Venclyxto 100 mg film-coated tablets, Venclyxto 50 mg film-coated tablets, JNJ-75276617, JNJ-75276617, matching the 50 mg (G029), JNJ-75276617, Azacitidine betapharm 25 mg/mL powder for suspension for injection

    Janssen-Cilag International N.V.

    Acute Myeloid Luekemia

    phase 3 small molecule active

    1 trial

  17. JNJ-77242113, Film-Coated Tablet without JNJ-77242113

    Janssen-Cilag International N.V.

    Moderate to Severe Plaque Psoriasis

    phase 3 small molecule active

    1 trial

  18. JNJ-77242113, Film-Coated Tablet without JNJ-77242113, Film-Coated Tablet without Deucravacitinib, DEUCRAVACITINIB

    Janssen-Cilag International N.V.

    Moderate to Severe Plaque Psoriasis

    phase 3 small molecule active

    1 trial

  19. JNJ-77242113, Icotrokinra, JNJ-77242113-AAC Placebo tablet

    Janssen-Cilag International N.V.

    Moderately to Severely Active Crohn's Disease

    phase 3 small molecule active

    1 trial

  20. JNJ-77242113-AAC Placebo tablet, JNJ-77242113

    Janssen-Cilag International N.V.

    Active Psoriatic Arthritis

    phase 3 small molecule active

    1 trial

  21. JNJ-78278343, Docetaxel AqVida 20 mg/ml Konzentrat zur Herstellung einer Infusionslösung, JNJ-78278343, Prednison acis 5 mg, Tabletten, DOCETAXEL , PREDNISONE

    Janssen-Cilag International N.V.

    Metastatic Castration-resistant Prostate Cancer (mCRPC)

    phase 3 small molecule active

    1 trial

  22. JNJ-80202135, Placebo subcutaneous without Nipocalimab

    Janssen-Cilag International N.V.

    Systemic Lupus Erythematosus

    phase 3 small molecule active

    1 trial

  23. JNJ-80202135, Placebo subcutaneous without Nipocalimab

    Janssen-Cilag International N.V.

    Sjögren's Disease

    phase 3 small molecule active

    1 trial

  24. JNJ-90301900 (NBTXR3)

    Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

    Carcinoma, Squamous Cell

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources